Clinical trial Recruiting at 1 site Interventional Ages 18 to 64

Liposomal bupivacaine to reduce pain after VATS

Official title: The Efficacy and Safety of Liposomal Bupivacaine Plus Bupivacaine Local Incisional Infiltration for Postoperative Pain in Patients Undergoing Video-assisted Thoracoscopic Surgery:A Multi-Center Randomized Controlled Trial

Run by Beijing Tiantan Hospital · NCT07432711 · Data updated 2026-11-12

This test will see if a long‑acting liposomal bupivacaine injection at the incision eases postoperative pain for adults having VATS lung surgery.

More Pain Management trials

Quick facts

Study typeInterventional
Ages18 Years to 64 Years
SexAll
Enrollment100 (estimated)
SponsorBeijing Tiantan Hospital
Academic / other
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedMarch 2, 2026
Main results expectedMarch 30, 2027
Study endsJune 30, 2027
Registry record updatedJuly 14, 2026
Trial IDNCT07432711 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18–64 years old with ASA physical status I–III scheduled for elective VATS lobectomy or wedge resection who can give informed consent and have no chronic pain or other exclusion criteria.

Probably not a fit

Patients with chronic pain syndromes, certain cardiac conduction problems, unstable coronary disease, uncontrolled bleeding or coagulation disorders, insulin-treated diabetes, or those on unpaused anticoagulants are excluded and unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional trial compares incision-site local injection of standard bupivacaine to liposomal bupivacaine combined with bupivacaine in adults undergoing elective video-assisted thoracoscopic lobectomy or wedge resection. Participants receive the assigned local anesthetic at the surgical incision and are followed after surgery for pain scores, opioid consumption, and postoperative complications. Liposomal bupivacaine is a sustained-release formulation intended to provide analgesia for up to 72 hours, which the trial will test against conventional bupivacaine infiltration. Outcomes will focus on acute postoperative pain control and measures related to recovery and adverse events.

Why it matters

Potential benefit: If successful, this could provide longer-lasting incision-site pain relief after VATS, reduce opioid use, and speed recovery.

How similar studies have gone: Some prior studies have reported improved analgesia with liposomal bupivacaine versus standard local anesthetics, but results have been mixed and heterogeneous.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patients scheduled for elective video-assisted thoracoscopic lobectomy or wedge resection under general anesthesia;
2. Ages 18 to 64 years old;
3. American Society of Anesthesiologists (ASA) physical status of I-III;
4. Glasgow Coma Scale (GCS) score of 15;
5. Patients must be able to understand the nature and potential personal consequences of the clinical trial, signing of the informed consent form.

Exclusion Criteria:

1. History of chronic pain syndrome of any cause.
2. Patients with heart conduction block (sinus block or atrioventricular block).
3. Patients with unstable coronary artery disease.
4. Patients with gastric ulcer or gastric bleeding.
5. Patients with diabetes and are being treated with insulin.
6. Subjects with coagulation dysfunction (prothrombin time or activated partial thromboplastin time is higher than the normal threshold) or patients who are taking oral anticoagulants for other medical reasons and have not stopped it before surgery, such as warfarin or new anticoagulants rivaroxaban or dabigatran.
7. Patients with abnormal liver function: alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \> 2× the upper limit of normal (ULN) or total bilirubin (TBIL) ≥ 1.5×ULN.
8. Patients with renal impairment (serum creatinine \> 176 µmol/L) or receiving dialysis treatment within 28 days before surgery.
9. Patients with a history of diagnosed mental illness or currently taking psychotropic medication.
10. Excessive alcohol or drug abuse, chronic opioid use (more than 2 weeks or 3 days per week for more than 1 month), use of drugs with confirmed or suspected sedative or analgesic effects, or use of any painkiller within 24 h before surgery.
11. Pregnancy or breastfeeding.
12. Extreme body mass index (BMI) (\< 15 or \> 35).
13. Participation in another interventional trial that interferes with the intervention or outcome of this trial.
14. Patients with a history of allergy to local anaesthetics or one of the study drugs.

Where it's running

  • Beijing Tiantan Hospital
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.